337. Effect of palliative treatment with High Dose Rate intraluminal brachytherapy on survival in patients with advanced oesophageal cancer

Purpose The aim of this work was to analyse results of palliative HDR brachytherapy in patients with advanced esophageal cancer. Material and methods Nighty-one patients with unresectable, advanced esophageal cancer were treated palliatively by HDR brachytherapy. All patients received total dose of 22.5 Gy in three fractions every week. Remissions of dysphagia and other clinical and radiological factors were assessed in 1st month after the end of treatment, and then in 3d, 6th and 12th months. Survival rate was compared with choosen clinical factors using log-rank test and Kaplan Meier method. Results Median survival time in whole group of patients was 8.2 months. Median survival time according to received remission was, respectively – for CR – 14.6 months, for PR – 7.2 months, for NR – 3.8 months (Iog-rank p=00001, F Cox p= 0.00001). Longer median survival time we observed when tumor length was below 5 cm (12.1 months) then between 5 and 10 cm (7.8 months) or longer then 10 cm (6.4 months) (log-rank p=0.002). Longer median survival time we observed in clinical stage II (14.1 months) compared with clinical stage III (7.7 months) and IV (7.2 months) (log-rank p=0.01). Significant correlations were found between survival and Karnofsky performance status, grade of dysphagia and age. Conclusions Grade of remission assessed in 1st month after the end of treatment, age of patients and grade of dysphagia had influence on survival (confirmed in multivariate analysis). In univariate analysis important prognostic factors were also: Karnofsky performance status, clinical stage, length of tumour.